Print

Novartis (NVS) Highlights Key Data on Patients With Hematologic Diseases and Breast Cancer With More Than 140 Abstracts at American Society of Hematology And SABCS  
11/28/2012 8:30:54 AM

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

The American Society of Hematology (ASH) annual meeting in Atlanta, held December 8-11, will feature significant data across hematologic diseases including two-year follow-up data from Phase III trials of Jakavi® (ruxolitinib) in patients treated with Jakavi for myelofibrosis and data evaluating molecular response following treatment with Tasigna® (nilotinib) in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) compared with Glivec® (imatinib)* therapy. In addition, updated data on Exjade® (deferasirox) in non-transfusion-dependent thalassemia (NTDT), as well as new data on the removal of cardiac iron in Beta-thalassemia major, will be presented.

//-->